Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


A biochemical analysis linking APOBEC3A to disparate HIV-1 restriction and skin cancer.

Pham P, Landolph A, Mendez C, Li N, Goodman MF.

J Biol Chem. 2013 Oct 11;288(41):29294-304. doi: 10.1074/jbc.M113.504175. Epub 2013 Aug 26.


Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.

Love RP, Xu H, Chelico L.

J Biol Chem. 2012 Aug 31;287(36):30812-22. doi: 10.1074/jbc.M112.393181. Epub 2012 Jul 20.


Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B.

Adolph MB, Love RP, Feng Y, Chelico L.

Nucleic Acids Res. 2017 Nov 16;45(20):11925-11940. doi: 10.1093/nar/gkx832.


Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties.

Mitra M, Hercík K, Byeon IJ, Ahn J, Hill S, Hinchee-Rodriguez K, Singer D, Byeon CH, Charlton LM, Nam G, Heidecker G, Gronenborn AM, Levin JG.

Nucleic Acids Res. 2014 Jan;42(2):1095-110. doi: 10.1093/nar/gkt945. Epub 2013 Oct 24.


Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms.

Thielen BK, McNevin JP, McElrath MJ, Hunt BV, Klein KC, Lingappa JR.

J Biol Chem. 2010 Sep 3;285(36):27753-66. doi: 10.1074/jbc.M110.102822. Epub 2010 Jul 8.


The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization.

Bohn MF, Shandilya SMD, Silvas TV, Nalivaika EA, Kouno T, Kelch BA, Ryder SP, Kurt-Yilmaz N, Somasundaran M, Schiffer CA.

Structure. 2015 May 5;23(5):903-911. doi: 10.1016/j.str.2015.03.016. Epub 2015 Apr 23.


Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.

Ara A, Love RP, Chelico L.

PLoS Pathog. 2014 Mar 20;10(3):e1004024. doi: 10.1371/journal.ppat.1004024. eCollection 2014 Mar.


NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity.

Byeon IJ, Ahn J, Mitra M, Byeon CH, Hercík K, Hritz J, Charlton LM, Levin JG, Gronenborn AM.

Nat Commun. 2013;4:1890. doi: 10.1038/ncomms2883.


Efficient deamination of 5-methylcytidine and 5-substituted cytidine residues in DNA by human APOBEC3A cytidine deaminase.

Suspène R, Aynaud MM, Vartanian JP, Wain-Hobson S.

PLoS One. 2013 Jun 20;8(6):e63461. doi: 10.1371/journal.pone.0063461. Print 2013.


APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.

Hoopes JI, Cortez LM, Mertz TM, Malc EP, Mieczkowski PA, Roberts SA.

Cell Rep. 2016 Feb 16;14(6):1273-1282. doi: 10.1016/j.celrep.2016.01.021. Epub 2016 Jan 28.


Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G.

Harjes S, Solomon WC, Li M, Chen KM, Harjes E, Harris RS, Matsuo H.

J Virol. 2013 Jun;87(12):7008-14. doi: 10.1128/JVI.03173-12. Epub 2013 Apr 17.


Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.

Bulliard Y, Narvaiza I, Bertero A, Peddi S, Röhrig UF, Ortiz M, Zoete V, Castro-Díaz N, Turelli P, Telenti A, Michielin O, Weitzman MD, Trono D.

J Virol. 2011 Feb;85(4):1765-76. doi: 10.1128/JVI.01651-10. Epub 2010 Dec 1.


Dissecting APOBEC3G substrate specificity by nucleoside analog interference.

Rausch JW, Chelico L, Goodman MF, Le Grice SF.

J Biol Chem. 2009 Mar 13;284(11):7047-58. doi: 10.1074/jbc.M807258200. Epub 2009 Jan 9.


HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.

Feng Y, Love RP, Chelico L.

J Biol Chem. 2013 Mar 1;288(9):6083-94. doi: 10.1074/jbc.M112.421875. Epub 2013 Jan 11.


The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution.

Rathore A, Carpenter MA, Demir Ö, Ikeda T, Li M, Shaban NM, Law EK, Anokhin D, Brown WL, Amaro RE, Harris RS.

J Mol Biol. 2013 Nov 15;425(22):4442-54. doi: 10.1016/j.jmb.2013.07.040. Epub 2013 Aug 11.


A chimeric human APOBEC3A protein with a three amino acid insertion confers differential HIV-1 and adeno-associated virus restriction.

Wang Y, Wang Z, Pramanik A, Santiago ML, Qiu J, Stephens EB.

Virology. 2016 Nov;498:149-163. doi: 10.1016/j.virol.2016.08.001. Epub 2016 Aug 30.


An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.

Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA.

Nat Genet. 2015 Sep;47(9):1067-72. doi: 10.1038/ng.3378. Epub 2015 Aug 10.


Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution.

Senavirathne G, Jaszczur M, Auerbach PA, Upton TG, Chelico L, Goodman MF, Rueda D.

J Biol Chem. 2012 May 4;287(19):15826-35. doi: 10.1074/jbc.M112.342790. Epub 2012 Feb 23.


RNA-binding residues in the N-terminus of APOBEC3G influence its DNA sequence specificity and retrovirus restriction efficiency.

Bélanger K, Langlois MA.

Virology. 2015 Sep;483:141-8. doi: 10.1016/j.virol.2015.04.019. Epub 2015 May 15.


Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Epub 2005 Apr 13. Retraction in: Nature. 2010 Jul 8;466(7303):276.


Supplemental Content

Support Center